Lacosamid Neuraxpharm (Lacosamide)

Lacosamide is employed in the management of seizure disorders, particularly focal epileptic activity.

• Partial‑onset seizures (adults): reduces seizure frequency as add‑on therapy.
• Partial‑onset seizures (pediatric patients): provides adjunctive seizure control in children.
• Epilepsy (overall): contributes to broader seizure management when combined with other antiepileptic drugs.

• Lacosamide enhances the slow inactivation of voltage‑gated sodium channels, which stabilizes hyperexcitable neuronal membranes and diminishes repetitive neuronal firing. By selectively targeting the slow inactivation phase, it reduces the propagation of epileptiform activity without markedly affecting normal neuronal conduction.

Lacosamide may cause a range of adverse reactions, from mild to severe.

Common Side Effects

• Dizziness: sensation of light‑headedness or unsteadiness.
• Nausea: mild to moderate stomach upset.
• Fatigue: increased tiredness or lack of energy.
• Headache: mild to moderate cranial pain.
• Vision disturbances: blurred or double vision.
• Tremor: involuntary shaking of limbs.

Serious or Rare Side Effects

• Cardiac arrhythmia: abnormal heart rhythm, including PR‑interval prolongation.
• Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.
• Suicidal ideation: emergence of thoughts of self‑harm.
• Hepatic injury: signs of liver dysfunction such as jaundice.
• Acute pancreatitis: sudden abdominal pain with elevated enzymes.
• Hypersensitivity reactions: anaphylaxis or severe allergic response.

When prescribing Lacosamide, clinicians should consider several safety measures.

• Cardiac monitoring: assess ECG for PR‑interval changes, especially in patients with pre‑existing conduction disorders.
• Renal impairment: adjust dose in patients with reduced kidney function.
• Hepatic impairment: use caution and consider dose reduction in liver disease.
• Discontinuation: avoid abrupt cessation to prevent seizure exacerbation; taper gradually.
• Hypersensitivity: discontinue if signs of allergic reaction appear.
• Store at ambient temperature: keep below 25 °C, protect from moisture, and retain in original packaging.

Lacosamide can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Strong CYP3A4 inducers (e.g., carbamazepine, phenytoin): may markedly reduce lacosamide plasma levels.
• Other sodium‑channel blockers (e.g., lamotrigine, topiramate): increase risk of central nervous system depression.

Moderate Interactions (Monitor Closely)

• Oral contraceptives: lacosamide may decrease hormonal efficacy, requiring additional contraception.
• Antihypertensives: potential additive blood‑pressure lowering effect.
• Antidepressants (e.g., SSRIs): monitor for increased dizziness or somnolence.
• Anticoagulants (e.g., warfarin): observe INR for possible changes.
• Alcohol: may enhance central nervous system depression, advise moderation.